Long-term outcomes after intravesical therapy for non-muscle invasive bladder cancer are difficult to asses due to the lack of quality long-term data and inconsistencies in reporting results. It is clear that better long-term data are needed to define the impact of intravesical therapy on the natural history of the disease.